Jamshedpur Reporter

Post-Traumatic Stress Disorder Pipeline Assessment, 2023 Updates | Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka, Nobilis Therapeutics

 Breaking News
  • No posts were found

Post-Traumatic Stress Disorder Pipeline Assessment, 2023 Updates | Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka, Nobilis Therapeutics

May 24
17:50 2023
Post-Traumatic Stress Disorder Pipeline Assessment, 2023 Updates | Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka, Nobilis Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Post-Traumatic Stress Disorder pipeline constitutes 25+ key companies continuously working towards developing 25+ Post-Traumatic Stress Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Post-Traumatic Stress Disorder Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Traumatic Stress Disorder Market.

 

Some of the key takeaways from the Post-Traumatic Stress Disorder Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Post-Traumatic Stress Disorder treatment therapies with a considerable amount of success over the years. 
  • Post-Traumatic Stress Disorder companies working in the treatment market are Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Therapeutics, Bionomics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others, are developing therapies for the Post-Traumatic Stress Disorder treatment 
  • Emerging Post-Traumatic Stress Disorder therapies such as – Lu AG06466, EMP-01, BNC210, ALTO-100, ZP150, NYX-783, Brexpiprazole, NBTX-001, BNC 210, BI 1358894, BX-1, Lu AG06466, and others are expected to have a significant impact on the Post-Traumatic Stress Disorder market in the coming years.   
  • In October 2022, Osanetant (ACER-801), a medication for treating acute stress disorder and post-traumatic stress disorder (PTSD), has been given a new indication by Acer Therapeutics Inc
  • In September 2022, EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative being developed by atai Life Sciences N.V. for the treatment of post-traumatic stress disorder (PTSD) and other indications, has received the regulatory and ethics approvals needed from Medsafe and HDEC, respectively, to begin enrolling participants in the study’s Phase 1
  • In May 2022, A poster containing information from preclinical tests of Aptinyx’s NYX-783 in PTSD model organisms was displayed at the American Psychiatric Association Annual Meeting, which took place in New Orleans, Louisiana, from May 21 to 25, 2022
  • In May 2022, A research and development partnership between Beckley Psytech Limited and Lophora ApS was announced. According to the terms of the agreement, Beckley Psytech will collaborate widely on R&D as well as jointly fund the continued development of the Lophora pipeline

 

Post-Traumatic Stress Disorder Overview

People who have encountered or witnessed a traumatic incident, such as a natural disaster, a catastrophic accident, a terrorist attack, war/combat, or rape, or who have been threatened with death, physical assault, or serious injury, may develop post-traumatic stress disorder (PTSD), a psychiatric disease.

 

Get a Free Sample PDF Report to know more about Post-Traumatic Stress Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight

 

Emerging Post-Traumatic Stress Disorder Drugs Under Different Phases of Clinical Development Include:

  • Lu AG06466: Lundbeck
  • EMP-01: Atai Life Sciences
  • BNC210: Bionomics Limited
  • Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
  • ALTO-100: Alto Neuroscienc
  • NBTX-001 Xenon Inhaler: Nobilis Therapeutics
  • ZP150: Jazz Pharmaceuticals
  • NYX-783: Aptinyx
  • Brexpiprazole: Otsuka Pharmaceuticals
  • NBTX-001: Nobilis Therapeutics
  • BNC 210: Bionomics
  • BI 1358894: Boehringer Ingelheim
  • BX-1: Bionorica SE
  • Lu AG06466: H. Lundbeck A/S

 

Route of Administration

Post-Traumatic Stress Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Post-Traumatic Stress Disorder Pipeline Therapeutics Assessment

  • Post-Traumatic Stress Disorder Assessment by Product Type
  • Post-Traumatic Stress Disorder By Stage and Product Type
  • Post-Traumatic Stress Disorder Assessment by Route of Administration
  • Post-Traumatic Stress Disorder By Stage and Route of Administration
  • Post-Traumatic Stress Disorder Assessment by Molecule Type
  • Post-Traumatic Stress Disorder by Stage and Molecule Type

 

DelveInsight’s Post-Traumatic Stress Disorder Report covers around 25+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Post-Traumatic Stress Disorder product details are provided in the report. Download the Post-Traumatic Stress Disorder pipeline report to learn more about the emerging Post-Traumatic Stress Disorder therapies

 

Some of the key companies in the Post-Traumatic Stress Disorder Therapeutics Market include:

Key companies developing therapies for Post-Traumatic Stress Disorder are – ptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others.

 

Post-Traumatic Stress Disorder Pipeline Analysis:

The Post-Traumatic Stress Disorder pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
  • Post-Traumatic Stress Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Post-Traumatic Stress Disorder drugs and therapies

 

Post-Traumatic Stress Disorder Pipeline Market Drivers

  • Increase in prevalence, increased initiatives to create public awareness and knowledge of disease are some of the important factors that are fueling the Post-Traumatic Stress Disorder Market.

 

Post-Traumatic Stress Disorder Pipeline Market Barriers

  • However, heterogeneity of the symptoms, delayed-onset PTSD and other factors are creating obstacles in the Post-Traumatic Stress Disorder Market growth.

 

Scope of Post-Traumatic Stress Disorder Pipeline Drug Insight    

  • Coverage: Global
  • Key Post-Traumatic Stress Disorder Companies: Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Therapeutics, Bionomics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others
  • Key Post-Traumatic Stress Disorder Therapies: Lu AG06466, EMP-01, BNC210, ALTO-100, ZP150, NYX-783, Brexpiprazole, NBTX-001, BNC 210, BI 1358894, BX-1, Lu AG06466, and others
  • Post-Traumatic Stress Disorder Therapeutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
  • Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers 

 

Request for Sample PDF Report for Post-Traumatic Stress Disorder Pipeline Assessment and clinical trials

 

Table of Contents

1

Post-Traumatic Stress Disorder Report Introduction

2

Post-Traumatic Stress Disorder Executive Summary

3

Post-Traumatic Stress Disorder Overview

4

Post-Traumatic Stress Disorder- Analytical Perspective In-depth Commercial Assessment

5

Post-Traumatic Stress Disorder Pipeline Therapeutics

6

Post-Traumatic Stress Disorder Late Stage Products (Phase II/III)

7

Post-Traumatic Stress Disorder Mid Stage Products (Phase II)

8

Post-Traumatic Stress Disorder Early Stage Products (Phase I)

9

Post-Traumatic Stress Disorder Preclinical Stage Products

10

Post-Traumatic Stress Disorder Therapeutics Assessment

11

Post-Traumatic Stress Disorder Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Post-Traumatic Stress Disorder Key Companies

14

Post-Traumatic Stress Disorder Key Products

15

Post-Traumatic Stress Disorder Unmet Needs

16 

Post-Traumatic Stress Disorder Market Drivers and Barriers

17

Post-Traumatic Stress Disorder Future Perspectives and Conclusion

18

Post-Traumatic Stress Disorder Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Recent Posts

Improve Work Tasks by Pairing INNOCN 27 Inch Monitor 27G1H with the Spacetop

Read Full Article

Categories